ASLAN Pharmaceuticals Limited (ASLN)

0.4516 -0.0034 (-0.75%) At close: 04:00PM EDT

ASLAN Pharmaceuticals Limited

83 Clemenceau Avenue
No. 12-03 UE Square
Singapore 239920
Singapore
65 6222 4235
https://aslanpharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 27

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Carl Alan Jason Morton Firth EMBA, Ph.D.	Founder, CEO & Exec. Director	N/A	N/A	1973
Mr. Kiran Kumar Asarpota	COO & Head of Fin.	N/A	N/A	1979
Mr. Ben Goodger	Gen. Counsel	N/A	N/A	1963
Mr. Stephen Doyle	Chief Bus. Officer	N/A	N/A	1973
Charlie Hsu	Investor Relations Director	N/A	N/A	N/A
Chi-Chin Wang	IR & Corp. Devel. Director	N/A	N/A	N/A
Dr. Alexandre Kaoukhov M.D.	Chief Medical Officer	N/A	N/A	1974

Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.

Corporate Governance

ASLAN Pharmaceuticals Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.